The invention relates to a vaccine against herpes simplex virus (HSV) comprising
an invasive but attenuated or non-pathogenic bacterium, which bacterium comprises
a coding sequence encoding a HSV antigen in a form that enables said coding sequence
to be transferred to a host cell of a human or animal host which the bacterium
is capable of invading and to be expressed in said cell to form said antigen without
the introduction of an antimicrobial agent to lyse the bacterium. The invention
also provides similar vaccines against other viruses.
